Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
About Definitive Healthcare Corp. (DH)
Definitive Healthcare Corp. (Nasdaq: DH) is a leading provider of healthcare commercial intelligence, delivering actionable data and insights to organizations across the healthcare ecosystem. The company's mission is to transform data, analytics, and expertise into meaningful intelligence that enables its clients to uncover opportunities, optimize strategies, and drive growth. By leveraging a robust SaaS-based platform, Definitive Healthcare empowers clients to navigate the complexities of the healthcare market with precision and confidence.
Comprehensive Data and Analytics Platform
At the core of Definitive Healthcare's offerings is its proprietary platform, which aggregates and analyzes data on over 8,100 hospitals, 7,300 ambulatory surgery centers, 11,000 imaging centers, 38,000 long-term care facilities, 1,200 accountable care organizations (ACOs) and health information exchanges (HIEs), 197,000 physician groups, 1.3 million physicians, and 750 Canadian hospitals. This extensive dataset provides clients with unparalleled visibility into the healthcare provider landscape, enabling them to make informed decisions in areas such as market segmentation, sales execution, and product development.
Key Solutions and Products
- Monocl ExpertInsight: A comprehensive tool that delivers data on more than 15 million medical experts globally, helping pharmaceutical and medtech companies enhance Key Opinion Leader (KOL) engagement and clinical collaboration.
- Population Intelligence: Combines clinical and consumer data to enable precision marketing, allowing businesses to identify and target specific audience segments effectively.
- Carevoyance: A solution tailored for medtech sales teams, providing deep insights into provider segmentation, territory alignment, and sales tracking to streamline workflows and accelerate device adoption.
- Market Forecast: A predictive analytics tool that offers three, five, and ten-year market trend projections, helping healthcare organizations plan strategically for future demand and growth opportunities.
- DH View Suite: A mobile-enabled platform that equips sales and marketing teams with instant access to critical intelligence on healthcare professionals and organizations, enhancing productivity and client engagement.
- Monocl Conferences: A specialized solution for life sciences organizations to optimize conference planning and participation, providing insights into key presentations, trending topics, and expert engagement opportunities.
Market Position and Competitive Landscape
Operating within the rapidly evolving healthcare data analytics industry, Definitive Healthcare stands out for its depth of data, innovative solutions, and focus on healthcare-specific use cases. Its competitors include companies like IQVIA and Truveta, but Definitive Healthcare differentiates itself through its tailored SaaS offerings and the integration of predictive analytics with real-time data visualization. The company's solutions address critical challenges faced by healthcare organizations, such as identifying high-growth markets, optimizing sales territories, and enhancing patient engagement strategies.
Revenue Model and Geographic Focus
Definitive Healthcare generates the majority of its revenue through subscription-based services, offering scalable solutions that cater to organizations of all sizes. While its primary market is the United States, the company also provides data on international healthcare providers, particularly in Canada, further broadening its client base and market reach.
Challenges and Opportunities
As a data-centric organization, Definitive Healthcare faces challenges such as ensuring the accuracy and comprehensiveness of its datasets, navigating complex regulatory environments, and mitigating cybersecurity risks. However, its investments in proprietary data science, AI-driven analytics, and user-friendly interfaces position it well to address these challenges and capitalize on growing demand for healthcare intelligence solutions.
Conclusion
Definitive Healthcare Corp. is a pivotal player in the healthcare commercial intelligence space, enabling organizations to unlock new opportunities and optimize their operations through data-driven insights. With its diverse product portfolio, deep industry expertise, and commitment to innovation, Definitive Healthcare continues to shape the future of the healthcare market, providing clients with the tools they need to succeed in an increasingly competitive landscape.
Definitive Healthcare (DH) reported mixed Q4 and full-year 2024 results. Q4 revenue declined 6% to $62.3 million, while full-year revenue slightly increased to $252.2 million. The company recorded significant goodwill impairment charges of $97.1 million in Q4 and $688.9 million for the full year.
Q4 highlights include: Net Loss of $(84.7) million, Adjusted Net Income of $12.6 million, and Adjusted EBITDA of $17.5 million (28% margin). Full-year metrics showed improvement in cash flow operations, up 41% to $58.2 million, and Unlevered Free Cash Flow increased 6% to $72.5 million.
The company announced Casey Heller will become CFO effective June 2, 2025. For 2025, DH projects revenue between $230.0-$240.0 million and Adjusted EBITDA of $61.0-$65.0 million with 26-28% margin.
Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the upcoming Raymond James 2025 Institutional Investors Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Tuesday, March 4, 2025, at 3:25 p.m. Eastern Time.
Investors and interested parties can access the live presentation through a webcast available on the Events page of Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. A recorded version of the presentation will be accessible for a time after the event.
Definitive Healthcare (Nasdaq: DH), a healthcare commercial intelligence company, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results.
Investors can access the live audio webcast through the company's Investor Relations website at ir.definitivehc.com. A dial-in option will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). A replay will be accessible through March 29, 2025, using 800-645-7964 or 757-849-6722 with passcode 1765#.
Definitive Healthcare (Nasdaq: DH) has been named among Built In's 100 Best Places to Work in Boston for 2025. The recognition, which includes companies of various sizes and both remote-first and traditional employers, highlights DH's commitment to employee satisfaction and workplace culture.
CEO Kevin Coop emphasized the company's focus on making an impact in healthcare and fostering a culture of innovation where employees are empowered to contribute. The selection process by Built In evaluated compensation, benefits, and various workplace attributes including remote work opportunities, DEI programs, and cultural offerings.
The company offers notable benefits including unlimited PTO, hybrid work options, and half-day Summer Fridays for U.S. employees. DH also provides extensive professional development opportunities through continuous learning, leadership development, and educational support programs. This recognition reflects the company's dedication to creating an environment where innovation and individual growth flourish while maintaining work-life balance.
Definitive Healthcare (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the 27th Annual Needham Growth Conference. CEO Kevin Coop and CFO Rick Booth will deliver a presentation on Wednesday, January 15, 2025, at 2:15 p.m. Eastern Time.
Definitive Healthcare reported Q3 2024 financial results with revenue of $62.7 million, a 4% decrease from Q3 2023. Net loss was $(187.8) million, including goodwill impairment charges of $228.2 million. Adjusted net income rose to $15.4 million from $14.6 million, while adjusted EBITDA fell 5% to $20.6 million. Cash flow from operations was $19.4 million, and unlevered free cash flow was $24.3 million. The company announced a $100 million stock repurchase program starting in 2025. Customer base grew to 530 enterprise clients. CFO Richard Booth will leave by June 1, 2025. Q4 2024 revenue guidance is $60.0-$61.0 million, adjusted net income $10.5-$11.5 million, and full-year 2024 revenue is expected to be $250.0-$251.0 million.
Definitive Healthcare (Nasdaq: DH) has scheduled its third quarter 2024 financial results announcement for Thursday, November 7, 2024, after market close. The healthcare commercial intelligence company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's IR website and join via phone using domestic (877-358-7298) or international (+1-848-488-9244) dial-in numbers. A replay will be available until December 7, 2024.
Definitive Healthcare (Nasdaq: DH) has launched Monocl Conferences, a solution designed to enhance conference planning and participation for life science organizations. This intuitive platform provides medical affairs, marketing, and conference planning teams with rich, contextualized conference data and access to key experts.
Key features include:
- Visualized conference data dashboard
- Searchable conference insights
- Comparable data for monitoring trends
Monocl Conferences offers quick access to presentations, competitor analysis, social media insights, and details about centers of excellence. It aims to streamline planning, drive strategic engagement, and support organizations in delivering innovative therapies and medical devices to improve patient outcomes.
Definitive Healthcare (Nasdaq: DH) has launched Market Forecast, a predictive analytics solution designed to help healthcare organizations identify high-growth markets and service line opportunities. This new tool provides three, five, and 10-year market trend projections to strengthen strategic planning around future demand and growth opportunities.
Market Forecast aims to empower business development teams, service line leaders, and strategy executives by delivering year-over-year growth rate and market demand projections. This enables healthcare organizations to:
- Drive improved patient acquisition and retention
- Plan market expansion
- Allocate resources more effectively
The solution is particularly valuable for academic medical centers and other healthcare providers looking to identify services with the greatest potential for future growth, even when current volumes may not reflect that opportunity.
Definitive Healthcare Corp. (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Rick Booth, the company's Chief Financial Officer, is scheduled to present on Thursday, September 5, 2024, at 8:30 a.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the Events page on Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. For those unable to attend the live event, a replay of the webcast will be available for a time after the presentation.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
What does Definitive Healthcare Corp. do?
What industries does Definitive Healthcare serve?
How does Definitive Healthcare generate revenue?
What are some of Definitive Healthcare's key products?
What makes Definitive Healthcare unique in its industry?
Who are Definitive Healthcare's competitors?
What challenges does Definitive Healthcare face?
What geographic regions does Definitive Healthcare cover?
What is Monocl ExpertInsight?
How does Population Intelligence benefit businesses?
